Compare Stocks: EPRX, MESO, COAG, and AGIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$33.22 -1.1%	$35.18	$22.24 ▼ $46.00	$2.01B	0.6	797,477 shs	762,208 shs
COAG Hemab Therapeutics	$40.47 +2.7%	$46.34	$23.00 ▼ $55.42	$1.84B	N/A	336,458 shs	459,470 shs
EPRX Eupraxia Pharmaceuticals	$8.07 -4.2%	$6.87	$5.16 ▼ $9.32	$547.46M	1.07	521,173 shs	432,120 shs
MESO Mesoblast	$15.02 -3.0%	$16.18	$13.05 ▼ $21.50	$2.01B	2.12	197,731 shs	173,211 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	+1.51%	+0.12%	+5.59%	-8.65%
COAG Hemab Therapeutics	0.00%	-11.28%	-28.29%	+57.10%	+3,939,999,900.00%
EPRX Eupraxia Pharmaceuticals	0.00%	+0.24%	+25.30%	+35.37%	+57.97%
MESO Mesoblast	0.00%	-10.62%	-0.77%	+12.50%	+4.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$33.22 -1.1%	$35.18	$22.24 ▼ $46.00	$2.01B	0.6	797,477 shs	762,208 shs
COAG Hemab Therapeutics	$40.47 +2.7%	$46.34	$23.00 ▼ $55.42	$1.84B	N/A	336,458 shs	459,470 shs
EPRX Eupraxia Pharmaceuticals	$8.07 -4.2%	$6.87	$5.16 ▼ $9.32	$547.46M	1.07	521,173 shs	432,120 shs
MESO Mesoblast	$15.02 -3.0%	$16.18	$13.05 ▼ $21.50	$2.01B	2.12	197,731 shs	173,211 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	+1.51%	+0.12%	+5.59%	-8.65%
COAG Hemab Therapeutics	0.00%	-11.28%	-28.29%	+57.10%	+3,939,999,900.00%
EPRX Eupraxia Pharmaceuticals	0.00%	+0.24%	+25.30%	+35.37%	+57.97%
MESO Mesoblast	0.00%	-10.62%	-0.77%	+12.50%	+4.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.55	Moderate Buy	$41.25	24.17% Upside
COAG Hemab Therapeutics	2.57	Moderate Buy	$51.40	27.01% Upside
EPRX Eupraxia Pharmaceuticals	2.89	Moderate Buy	$18.00	123.05% Upside
MESO Mesoblast	2.00	Hold	$39.00	159.65% Upside

Current Analyst Ratings Breakdown

Latest EPRX, MESO, COAG, and AGIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	MESO Mesoblast	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$35.00 ➝ $39.00
8/24/2026	AGIO Agios Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/13/2026	COAG Hemab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D+)
8/12/2026	COAG Hemab Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$55.00 ➝ $64.00
8/11/2026	COAG Hemab Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $60.00
8/7/2026	AGIO Agios Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$31.00 ➝ $34.00
7/31/2026	AGIO Agios Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$46.00 ➝ $52.00
7/31/2026	AGIO Agios Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$41.00 ➝ $39.00
7/30/2026	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $55.00
7/21/2026	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$54.00 ➝ $52.00
7/17/2026	EPRX Eupraxia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$54.03M	36.71	N/A	N/A	$20.46 per share	1.62
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A
MESO Mesoblast	$120.25M	16.22	N/A	N/A	$4.38 per share	3.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-35.67%	-33.06%	10/29/2026 (Estimated)
COAG Hemab Therapeutics	N/A	-$24.78	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	-$38.58M	-$1.02	N/A	N/A	N/A	N/A	-63.97%	-43.32%	11/3/2026 (Estimated)
MESO Mesoblast	-$57.50M	-$0.28	N/A	41.72	N/A	N/A	N/A	N/A	N/A

Latest EPRX, MESO, COAG, and AGIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	COAG Hemab Therapeutics	-$0.63	-$0.80	-$0.17	-$0.80	N/A	N/A
8/11/2026	Q2 2026	EPRX Eupraxia Pharmaceuticals	-$0.25	-$0.23	+$0.02	-$0.23	N/A	N/A
7/31/2026	Q4 2026	MESO Mesoblast	N/A	-$0.0660	N/A	-$0.0660	N/A	$34.45 million
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	10.22	9.79
COAG Hemab Therapeutics	N/A	35.85	35.85
EPRX Eupraxia Pharmaceuticals	0.02	16.00	16.00
MESO Mesoblast	0.19	2.43	2.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
COAG Hemab Therapeutics	N/A
EPRX Eupraxia Pharmaceuticals	N/A
MESO Mesoblast	1.43%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	5.40%
COAG Hemab Therapeutics	N/A
EPRX Eupraxia Pharmaceuticals	N/A
MESO Mesoblast	18.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	540	59.70 million	56.48 million	Optionable
COAG Hemab Therapeutics	59	46.71 million	N/A	N/A
EPRX Eupraxia Pharmaceuticals	49	65.02 million	N/A	N/A
MESO Mesoblast	108	129.88 million	105.46 million	Optionable

EPRX, MESO, COAG, and AGIO Headlines

Recent News About These Companies

How Mesoblast Limited (MESO) Affects Rotational Strategy Timing

September 6, 2026 | news.stocktradersdaily.comN

Mesoblast (NASDAQ:MESO) Share Price Passes Above 50 Day Moving Average - Time to Sell?

September 4, 2026 | marketbeat.com

Bank of America Corp DE Increases Holdings in Mesoblast Limited $MESO

September 4, 2026 | marketbeat.com

Why brokers see 85% upside for this ASX biotech stock

September 4, 2026 | msn.com

Experts tip these $3 billion ASX shares to deliver over 75% returns

September 1, 2026 | msn.com

Mesoblast (NASDAQ:MESO) Shares Gap Up - Here's Why

August 27, 2026 | marketbeat.com

Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript

August 27, 2026 | seekingalpha.com

Mesoblast Reports Substantial Revenue Growth to US$120M

August 26, 2026 | globenewswire.com

Mesoblast H2 Earnings Call Highlights

August 26, 2026 | marketbeat.com

Mesoblast earnings: Strong revenue growth and operational milestones in FY26

August 26, 2026 | msn.com

Mesoblast Files 2026 Form 20-F, Affirms Status as Well-Known Issuer

August 26, 2026 | tipranks.com

Mesoblast to Outline 2026 Results and Pipeline Progress in Investor Webcast

August 24, 2026 | tipranks.com

Mesoblast Issues 875,000 Unquoted Employee Incentive Options

August 24, 2026 | tipranks.com

Mesoblast Increases Director Philip Krause’s Equity-Based Incentives

August 24, 2026 | tipranks.com

Mesoblast (NASDAQ:MESO) Shares Gap Down - Time to Sell?

August 21, 2026 | marketbeat.com

Mesoblast shares jump as Phase 3 chronic back pain trial completes patient treatment

August 19, 2026 | msn.com

MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up

August 18, 2026 | zacks.com

Mesoblast Completes Pivotal Phase 3 Patient Treatment for Chronic Low Back Pain

August 18, 2026 | tipranks.com

Mesoblast share price jumps on blockbuster news

August 17, 2026 | fool.com.au

Mesoblast shares are up sharply. Is this biotech still undervalued?

August 17, 2026 | msn.com

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

August 16, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, MESO, COAG, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$33.22 -0.38 (-1.13%)

Closing price 04:00 PM Eastern

Extended Trading

$33.14 -0.09 (-0.26%)

As of 07:30 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Hemab Therapeutics NASDAQ:COAG

$40.47 +1.07 (+2.72%)

As of 04:00 PM Eastern

We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$8.07 -0.35 (-4.16%)

Closing price 04:00 PM Eastern

Extended Trading

$8.31 +0.24 (+3.02%)

As of 07:30 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Mesoblast NASDAQ:MESO

$15.02 -0.46 (-2.97%)

Closing price 04:00 PM Eastern

Extended Trading

$15.02 0.00 (-0.03%)

As of 07:30 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPRX, MESO, COAG, and AGIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPRX, MESO, COAG, and AGIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPRX, MESO, COAG, and AGIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, MESO, COAG, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Hemab Therapeutics NASDAQ:COAG

Eupraxia Pharmaceuticals NASDAQ:EPRX

Mesoblast NASDAQ:MESO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPRX, MESO, COAG, and AGIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPRX, MESO, COAG, and AGIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPRX, MESO, COAG, and AGIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, MESO, COAG, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Hemab Therapeutics NASDAQ:COAG

Eupraxia Pharmaceuticals NASDAQ:EPRX

Mesoblast NASDAQ:MESO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools